When we are writing these words, the first quarter of 2018 is not even fully over yet, and CHR’s investigators have already seen 10 peer reviewed papers published according to PubMed. CHR is very obviously again looking at another record year in its research activities. We are particularly excited about our collaboration with the Brivanlou Laboratory for Stem Cell Biology and Molecular Embryology at Rockefeller University, where some truly remarkable things are happening. One project will be for the first time revealed by members of the Brivanlou Laboratory at CHR’s GrandRounds on Tuesday, April 10, 2018 at Jade Sixty, 116 East 60th Street. Reported data will have a very significant impact on the controversy swirling around preimplantation genetic screening (PGS), now also called preimplantation genetic testing for aneuploidy (PGT-A).
Capacity is limited. We, therefore, recommend early reservations for everybody who is interested in attending. As always, cocktails start at 6pm, followed by the GrandRounds lecture between 7-8pm and, finally, a sit-down dinner, starting at 8pm. For reservations, please email ykizawa@thechr.com.
In this issue of the VOICE, we cover:
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
DISCOVER YOUR TREATMENT OPTIONS
